查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1490030

全球慢性阻塞性肺病(COPD) 治疗市场：依药物类别、给药途径、通路及地区划分

Global Chronic Obstructive Pulmonary Disease Treatment Market, By Drug Class (Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Corticosteroids, Others), By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 178 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球慢性阻塞性肺病（COPD）治疗市场预计2024年为192.1亿美元，预计2031年将达到283.7亿美元，2024年至2031年的复合年增长率为5.7%。

报告范围 报告详情
基准年 2023年 2024年市场规模 192.1亿美元
实际资料 2019年至2023年 预测期 从2024年到2031年
预测 2024-2031 年复合年增长率： 5.70% 2031年价值预测 283.7亿美元
图：2024 年按地区分類的慢性阻塞性肺病(COPD) 治疗市场占有率(%)
全球慢性阻塞性肺病治疗市场-IMG1

慢性阻塞性肺病（COPD）是指一组导致气流阻塞和呼吸相关问题的肺部疾病。包括肺气肿和慢性支气管炎。慢性阻塞性肺病的主要原因包括吸烟、职场时接触肺部刺激物（如灰尘和烟雾）以及空气污染。 COPD 的主要症状包括呼吸短促、咳嗽、产生黏液（痰）和喘息。随着慢性阻塞性肺病的进展，肺功能会随着时间的推移而下降，导致呼吸困难。

市场动态：

全球慢性阻塞性肺病（COPD）治疗市场的成长是由吸烟率高、全球空气污染水平上升、老年人口增加以及对该疾病和可用治疗方案认识的提高所推动的。然而，缺乏对慢性阻塞性肺病和肺癌等相关併发症的完整治疗方法可能会阻碍市场成长。製药公司正在投资研发治疗慢性阻塞性肺病的新型生物製药，这能为市场成长提供利润丰厚的机会。该公司正在开发肾上腺素自动注射器、支气管扩张剂、吸入性皮质类固醇和联合治疗，以有效治疗慢性阻塞性肺病症状和病情恶化。

本研究的主要特点

  • 该报告详细分析了全球慢性阻塞性肺病（COPD）治疗市场，包括市场规模（十亿美元）和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球慢性阻塞性肺病(COPD) 治疗市场的主要企业进行概况分析。
  • 主要企业包括阿斯特捷利康、Orion Corporation、Mylan NV、Teva Pharmaceutical Industries Ltd.、GSK plc、Novartis AG、Sunovion Pharmaceuticals, Inc、CHIESI Farmaceutici SpA、Alembic Pharmaceuticals Ltd、Verona Pharmaceuticals、Theravance Biopharma Ltd、赛诺菲、勃林格殷格翰国际有限公司、默克公司、Grifols, SA、Almirall, SA、Genentech, Inc.
  • 该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
  • 全球慢性阻塞性肺病（COPD）治疗市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过用于分析全球慢性阻塞性肺病（COPD）治疗市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 影响分析
  • 流行病学
  • 市场趋势
  • 主要进展
  • 监管场景
  • 製造商收益
  • 收购和合作场景
  • 产品发布/核准
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

第四章全球慢性阻塞性肺病(COPD) 治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 对市场的影响

第五章全球慢性阻塞性肺病（COPD）治疗市场，依药物类别，2019-2031

  • 支气管扩张剂
  • 磷酸二酯酶4抑制剂
  • 皮质类固醇
  • 其他的

第六章全球慢性阻塞性肺病（COPD）治疗市场，依给药途径，2019-2031

  • 口服
  • 吸入

第7章2019-2031年全球慢性阻塞性肺病（COPD）治疗市场（依通路）

  • 医院药房
  • 零售药房
  • 网路药房

第8章2019-2031年全球慢性阻塞性肺病（COPD）治疗市场（按地区）

第9章 竞争格局

  • 公司简介
    • AstraZeneca
    • Orion Corporation
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA
    • Alembic Pharmaceuticals Ltd
    • Verona Pharmaceuticals
    • Theravance Biopharma
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Merck &Co., Inc
    • Grifols, SA
    • Almirall, SA
    • Genentech, Inc

第10章分析师建议

  • Wheel of Fortune
  • 分析师观点
  • Coherent Opportunity Map

第十一章 参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI2656

Global chronic obstructive pulmonary disease (COPD) treatment market is estimated to be valued at USD 19.21 Bn in 2024 and is expected to reach USD 28.37 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 19.21 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 5.70% 2031 Value Projection: US$ 28.37 Bn
Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region, 2024
Global Chronic Obstructive Pulmonary Disease Treatment Market - IMG1

Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.

Market Dynamics:

Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.

Key Features of the Study:

  • This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation-

  • By Drug Class:
    • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
    • Phosphodiesterase Type 4 Inhibitors
    • Corticosteroids
    • Others
  • By Route of Administration:
    • Oral
    • Inhalation
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca
    • Orion Corporation
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA
    • Alembic Pharmaceuticals Ltd
    • Verona Pharmaceuticals
    • Theravance Biopharma
    • Hoffmann-La Roche Ltd
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc
    • Grifols, S.A.
    • Almirall, S.A
    • Genentech, Inc

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Epidemiology
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Manufacturer Revenue
  • Acquisitions and Partnerships Scenario
  • Product Launches/Approvals
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Bronchodilators
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Phosphodiesterase Type 4 Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Corticosteroids
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Inhalation
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
      • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
      • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
      • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
      • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • AstraZeneca*
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Orion Corporation
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mylan N.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sunovion Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • CHIESI Farmaceutici SpA
    • Alembic Pharmaceuticals Ltd
    • Verona Pharmaceuticals
    • Theravance Biopharma
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc
    • Grifols, S.A.
    • Almirall, S.A
    • Genentech, Inc

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact